EGF-Receptor Targeted nanoparticles to Overcome Paclitaxel Resistant Breast Cancer

Grants and Contracts Details


I 1 . f· , . I'· ·1' .1·· . t I· .1 .. I [he goa 0 tl11S,propGsa is to uti llJ:: atargetcu l1anos~ stem to OVl:reOI111: ana treat rnu tI-urug resl,stant breast UillCCr.. ,Breast cancer. like many cancers are highly prone to multi-drug resistance due to the o\erexpressJOn of p-glycoprotcin (p-gp). The main hypothesis is that pac Iitaxel contain ing Iipid nanopartic les (1\ Ps) targeted to the epidermal growth factor receptor (EGFR) using transfom1ing growth factor-alpha (TGF-a)-coated nanoparticles may advantageously overcome resistance in human breast cancer cells over Taxo! or untargeted i\Ps. Preliminary in-vitro and ill-vivo supports that these J\ps may overcome resistance, and thus forms the basis of this proposal. The Eei F-receptor is present in the majority of breast cancers and is present at very high levels as compared to normal cells. TGF-cx has been shown to bind to a single class of high-affinity EGFR binding sites \\ ith dissociation constant
Effective start/end date4/12/066/30/07


  • National Cancer Institute: $300,759.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.